Department of Critical Care Medicine, Taizhou Hospital of Traditional Chinese Medicine, Taizhou, 225300, P.R. China.
Department of Nursing, Taizhou Hospital of Traditional Chinese Medicine, Taizhou, 225300, P.R. China.
Cell Mol Biol (Noisy-le-grand). 2022 Feb 27;67(6):228-235. doi: 10.14715/cmb/2021.67.6.30.
This study aimed to research the clinical effect of Xuebijing combined with thymosin α1 on patients with severe pneumonia complicated with sepsis, and its effect on serum inflammatory factors. For this purpose, 81 cases of severe pneumonia complicated with sepsis were collected. All patients were given early treatments. 41 cases who received Xuebijing injection by intravenous drip were selected as the control group. 40 cases who were treated through subcutaneous injection of thymosin α1 based on Xuebijing injection by intravenous drip were selected as the study group. The body temperature, respiration, heart rate, leukocytes, other general conditions, blood gas indexes, serum IL-6, TNF-α and CRP levels, bacterial clearance rate and therapy effect were recorded and compared before and after treatment. Results showed that after treatment, the body temperature, respiration, heart rate, leukocytes and other general conditions of the study group were lower than those in the control group (all p<0.05). The blood gas indexes pH and PaCO2 levels of the study group were lower than those of the control group. The levels of serum interleukin-6 (IL-6), serum tumor necrosis factor α (TNF-α) and C-reactive protein (CRP) in the study group were lower than those in the control group (all p<0.05). The bacterial clearance rate of the study group was lower than that of the control group (all p<0.05). The total effective rate of treatment of patients in the study group was higher than that of patients in the control group (all p<0.05). In general, Thymosin α1 and Xuebijing injection can improve the therapy effect of severe pneumonia complicated with sepsis, improve the hemorheology condition of patients, effectively remove bacteria and reduce the expression level of serum CRP, TNF-α, IL-6, IL-8 and other inflammatory factors in patients, which is worthy of clinical promotion.
本研究旨在探讨血必净联合胸腺肽α1 治疗重症肺炎合并脓毒症患者的临床效果及其对血清炎症因子的影响。为此，收集了 81 例重症肺炎合并脓毒症患者。所有患者均给予早期治疗。选择 41 例接受静脉滴注血必净注射液的患者作为对照组，选择 40 例在静脉滴注血必净注射液的基础上接受胸腺肽α1 皮下注射治疗的患者作为研究组。记录并比较治疗前后两组患者的体温、呼吸、心率、白细胞等一般情况、血气指标、血清白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）和 C 反应蛋白（CRP）水平、细菌清除率和治疗效果。结果显示，治疗后，研究组患者的体温、呼吸、心率、白细胞等一般情况均低于对照组（均 P<0.05），血气指标 pH 和 PaCO2 水平低于对照组，血清白细胞介素-6（IL-6）、血清肿瘤坏死因子-α（TNF-α）和 C 反应蛋白（CRP）水平低于对照组（均 P<0.05），细菌清除率低于对照组（均 P<0.05），治疗总有效率高于对照组（均 P<0.05）。综上所述，胸腺肽α1 与血必净注射液联合应用可提高重症肺炎合并脓毒症的治疗效果，改善患者血液流变学状况，有效清除细菌，降低患者血清 CRP、TNF-α、IL-6、IL-8 等炎症因子的表达水平，值得临床推广。
